Cytokines in cancer pathogenesis and cancer therapy
暂无分享,去创建一个
[1] G. Forni,et al. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy , 1988, Cancer and Metastasis Reviews.
[2] R. Zinkernagel. On natural and artificial vaccinations. , 2003, Annual review of immunology.
[3] Wancai Yang,et al. γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity , 2003, The Journal of experimental medicine.
[4] Hideo Negishi,et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.
[5] G. Dranoff,et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte–macrophage colony-stimulating factor-dependent fashion , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] F. Alt,et al. Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, Journal of Experimental Medicine.
[8] D. Hanahan,et al. Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells , 2003, The Journal of experimental medicine.
[9] Piero Musiani,et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. , 2003, The Journal of clinical investigation.
[10] Thomas Davis,et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] Ken Jung,et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Davidoff,et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. , 2003, Blood.
[13] Mark M. Davis,et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. , 2003, The Journal of clinical investigation.
[14] Y. Iwakura,et al. IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Neuberg,et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[17] V. Weinberg,et al. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Hodi,et al. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. , 2003, Cancer immunity.
[19] F. Belardelli,et al. ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8α+ Dendritic Cells , 2002, The Journal of experimental medicine.
[20] S. Pawlowski,et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. , 2002, Cancer research.
[21] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[22] S. Kaneko,et al. Prevention of Hepatocellular Carcinoma Development Associated with Chronic Hepatitis by Anti-Fas Ligand Antibody Therapy , 2002, The Journal of experimental medicine.
[23] A. Diefenbach,et al. The innate immune response to tumors and its role in the induction of T‐cell immunity , 2002, Immunological reviews.
[24] J. Lafaille,et al. Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.
[25] J. Trapani,et al. Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.
[26] T. Blankenstein,et al. Inhibition of Methylcholanthrene-induced Carcinogenesis by an Interferon γ Receptor–dependent Foreign Body Reaction , 2002, The Journal of experimental medicine.
[27] D. Neuberg,et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Hayday,et al. Resident Skin-specific γδ T Cells Provide Local, Nonredundant Regulation of Cutaneous Inflammation , 2002, The Journal of experimental medicine.
[29] K. Kärre. NK Cells, MHC Class I Molecules and the Missing Self , 2002, Scandinavian journal of immunology.
[30] G. Freeman,et al. The B7–CD28 superfamily , 2002, Nature Reviews Immunology.
[31] M. Smyth,et al. Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.
[32] R. Flavell,et al. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.
[33] C. Thompson,et al. Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells , 2001, The Journal of experimental medicine.
[34] A. Hayday,et al. Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.
[35] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[36] E. Shevach,et al. Control of T‐cell activation by CD4+ CD25+ suppressor T cells , 2001, Immunological reviews.
[37] H Nagura,et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.
[38] Rolf M. Zinkernagel,et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.
[39] C. Biron. Interferons α and β as Immune Regulators—A New Look , 2001 .
[40] Charles A. Janeway,et al. INAUGURAL ARTICLE by a Recently Elected Academy Member:How the immune system works to protect the host from infection: A personal view , 2001 .
[41] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[42] V. Sondak,et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[44] J. Egen,et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.
[45] Andrew V. Nguyen,et al. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.
[46] K. Uchida,et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. , 2001, Cancer research.
[47] P. Srivastava,et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. , 2001, Immunity.
[48] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[49] E. Jaffee,et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.
[50] M. Caligiuri,et al. Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells , 2001, The Journal of experimental medicine.
[51] J. Bluestone,et al. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.
[52] L. Grochow,et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M. Smyth,et al. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.
[54] Jay A. Berzofsky,et al. NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.
[55] R. Siegel,et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity , 2000, Nature Immunology.
[56] D. Hanahan,et al. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.
[57] G. Dranoff,et al. Cytokine-secreting tumor cell vaccines. , 2000, Current opinion in immunology.
[58] K. Seibert,et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.
[59] J. Trapani,et al. Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.
[60] H. Adami,et al. Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.
[61] Mark M. Davis,et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.
[62] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[63] M. Mihm,et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. , 2000, Cancer research.
[64] S. Soong,et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Carrington,et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.
[66] J. Trapani,et al. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.
[67] R. Ren,et al. Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder , 2000, Molecular and Cellular Biology.
[68] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[69] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[70] Y. Shima,et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. , 2000, Blood.
[71] G. Hannon,et al. A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.
[72] F. Marshall,et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.
[73] J. Sloan,et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] E. Sotomayor,et al. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. , 1999, Human gene therapy.
[75] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[76] G. Kollias,et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.
[77] N. Iizuka,et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo , 1999, British Journal of Cancer.
[78] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[79] R. Mulligan,et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. , 1999, Pathology.
[80] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[81] D. Neuberg,et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[82] Loise M. Francisco,et al. Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.
[83] M. Kris,et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[85] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[86] F. Chisari,et al. Immune Pathogenesis of Hepatocellular Carcinoma , 1998, The Journal of experimental medicine.
[87] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[88] T. Giese,et al. Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions , 1998, The Journal of experimental medicine.
[89] Lloyd J. Old,et al. New Paths in Human Cancer Serology , 1998, The Journal of experimental medicine.
[90] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[91] J. Waring,et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. , 1998, Blood.
[92] H. Heimpel,et al. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. , 1997, Journal of the National Cancer Institute.
[93] T. Tanimoto,et al. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. , 1997, Cancer research.
[94] P. Musiani,et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. , 1997, The American journal of pathology.
[95] P Signorelli,et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. , 1997, Journal of the National Cancer Institute.
[96] T. Blankenstein,et al. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. , 1997, Journal of immunology.
[97] J. Ferlay,et al. Cancer and infection: estimates of the attributable fraction in 1990. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[98] Robert E. Miller,et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo , 1997, Nature Medicine.
[99] F. Marshall,et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.
[100] M. Atkins,et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[101] M Aguet,et al. The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.
[102] R. Zinkernagel,et al. Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.
[103] J. Waring,et al. Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene , 1996, Cell.
[104] N. Shastri,et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[105] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[106] J. Ritz,et al. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[107] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[108] Y. Tao,et al. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[109] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] M. Pfreundschuh,et al. Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[111] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[112] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[113] S. Rudikoff,et al. Interleukin 6 is essential for in vivo development of B lineage neoplasms , 1995, The Journal of experimental medicine.
[114] W C Willett,et al. The causes and prevention of cancer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[115] W. Fair,et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] G. Dranoff,et al. Gene transfer as cancer therapy. , 1995, Advances in immunology.
[118] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[119] David Jones,et al. A personal view , 1992, Nature.
[120] K. Tracey,et al. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.
[121] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[122] S. Steinberg,et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.
[123] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[124] P. Leder,et al. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.
[125] A. Burgess,et al. Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .
[126] K. Ozato,et al. Two upstream elements activate transcription of a major histocompatibility complex class I gene in vitro. , 1992, Nucleic acids research.
[127] N. Renard,et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] T. Blankenstein,et al. Interleukin 7 induces CD4+ T cell-dependent tumor rejection , 1991, The Journal of experimental medicine.
[129] D. Pardoll,et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.
[130] E. Gilboa,et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.
[131] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[132] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[133] W. Paul. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response , 1989, Cell.
[134] A. Lacic. [A new look]. , 1989, Pielegniarka i polozna.
[135] I. Penn. Depressed immunity and the development of cancer. , 1981, Clinical and experimental immunology.
[136] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.